Neurostimulation Devices – Market Insights – United States

The US neurostimulation device market will be driven by continuous product innovation, including product launches and device improvements targeting expanded indications. Strategic market acquisitions—such as Boston Scientific acquiring Axonics—rapid uptake of novel technologies, and rising availability of products such as closed-loop SCS devices and minimally invasive tibial nerve stimulation devices will also contribute to this growth. However, the availability of alternative noninvasive treatment options and strict indication-specific requirements for reimbursement may limit the growth of the US neurostimulation market to some extent.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for neurostimulation devices in the US from 2019 through 2033.

The overall US neurostimulation device market will grow strongly over the forecast period.

Which factors are driving such strong market expansion?

How does growth vary in different device segments?

Which technological innovations are becoming available, and what is the adoption outlook?

HGNS devices are seeing increasing adoption.

What are the drivers supporting the HGNS device market?

Which new products are expected to enter this space?

Expanding indications and ongoing product launches by manufacturers are driving growth in the market.

How is the launch of new products affecting the competitive landscape?

How have companies performed with the recently received expanded indication approvals in the SCS device market?

How did product approvals and launches affect market performance in 2023?